Skip to main content

ImmunityBio, Inc.

IBRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001326110

In the last 90 days, ImmunityBio, Inc. insiders filed 0 open-market purchases and 2 sales; 405 institutions reported holding it in 13F filings for Q2 2026, worth $1.76B in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding ImmunityBio, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of IBRX: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders132126−6
Shares33.1M39.5M+6.38M (+19.3%)
Value$123.1M$196.3M+$73.3M (+59.6%)

New holders (17)

Institutions that held ImmunityBio, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to IBRX in Q3 2022
InstitutionSharesValue% of portfolio
Oracle Investment Management Inc315,322$1.57M0.90%
BNP Paribas Arbitrage, SA148,282$737.0K0.00%
Bank of Montreal97,760$517.0K0.00%
Marshall Wace, LLP51,590$256.0K0.00%
Sculptor Capital LP49,200$245.0K0.00%
Money Concepts Capital Corp30,122$150.0K0.01%
E Fund Management Co., Ltd.27,804$138.0K0.01%
CPWM, LLC23,630$117.0K0.01%
Virginia Retirement Systems Et Al14,100$70.1K0.00%
XTX Topco Ltd12,637$63.0K0.02%
Fishman Jay A Ltd10,000$49.7K0.01%
Nisa Investment Advisors, LLC5,160$27.0K0.00%
China Universal Asset Management Co., Ltd.3,749$19.0K0.01%
Institutional & Family Asset Management, LLC1,300$6.00K0.00%
Covington Capital Management250$1.00K0.00%
Parallel Advisors, LLC275$1.00K0.00%
Capital Advisors, Ltd. LLC74$00.00%

Sold out (23)

Institutions that held ImmunityBio, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.